rhGAA Formulation With M6P Glycans for Pompe Enzyme Stability
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Conventional recombinant human acid α-glucosidase (rhGAA) formulations for treating Pompe disease are complex and delicate, requiring careful preservation and administration, and often result in enzyme inactivation due to improper formulation components, leading to high treatment costs and inefficiencies.
Innovation Solution
A formulation comprising recombinant acid α-glucosidase expressed in Chinese hamster ovary (CHO) cells with increased mannose-6-phosphate residues, citrate or phosphate buffers, and excipients like mannitol and polysorbate 80, pH between 5.0 to 7.0, and optionally alkalizing or acidifying agents to maintain stability and activity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional recombinant human acid α-glucosidase (rhGAA) is used in enzyme replacement therapy, then the treatment can be administered to Pompe disease patients, but the enzyme activity and stability are lost during formulation, storage, transportation, and administration
Solution Approach 1:
The patent modifies the glycosylation parameters of rhGAA by expressing it in CHO cells, which naturally perform mammalian-style N-glycosylation. This results in glycans with terminal sialic acid residues that are negatively charged, creating electrostatic repulsion between enzyme molecules and preventing aggregation. The altered glycosylation state (increased sialylation) fundamentally changes the physical-chemical properties of the enzyme, enhancing its stability during storage and transportation.
Solution Approach 2:
The patent creates a composite structure where the rhGAA enzyme is combined with specifically modified N-glycan units that bear sialic acid residues. These glycans act as protective moieties that stabilize the enzyme structure and prevent degradation. The composite nature of the glycosylated enzyme provides enhanced stability compared to the non-glycosylated or differently glycosylated forms.
2Productivity
If conventional rhGAA formulations are used, then the enzyme can be delivered to patients, but non-productive clearance occurs and therapeutic efficacy is reduced
Solution Approach 1:
The patent changes the surface charge parameter of rhGAA through increased sialylation of N-glycans. The terminal sialic acid residues confer a negative charge to the enzyme surface, which alters its interaction with plasma proteins and cellular receptors. This parameter change reduces non-productive clearance by preventing unwanted binding to non-target tissues and extending plasma half-life, thereby improving therapeutic efficacy.
3Ease of manufacture
If standard enzyme formulations are used, then administration is possible, but high costs and inefficient treatment result due to enzyme degradation
Solution Approach 1:
The patent utilizes the natural capability of CHO cells to perform mammalian-style N-glycosylation during recombinant protein expression. The cell line inherently provides the enzymatic machinery needed to add sialic acid-containing glycans to the rhGAA enzyme. This self-service approach eliminates the need for complex post-translational modification steps or artificial stabilization additives, simplifying the formulation process while maintaining high enzyme stability and treatment efficiency.
Data Source
AI summary
Provided are pharmaceutical formulations comprising a recombinant acid α-glucosidase, wherein the recombinant acid α-glucosidase is expressed in Chinese hamster ovary (CHO) cells and comprises an increased content of N-glycan units bearing one or two mannose-6-phosphate residues when compared to a content of N-glycan units bearing one or two mannose-6-phosphate residues of alglucosidase alfa; at least one buffer selected from the group consisting of a citrate, a phosphate and combinations thereof; and at least one excipient selected from the group consisting of mannitol, polysorbate 80, and combinations thereof, wherein the formulation has a pH of from about 5.0 to about 7.0. Also provided are methods of treating Pompe disease using these pharmaceutical formulations.